Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP)

Bassetti, Matteo; Giacobbe, Daniele Roberto; Bruzzi, Paolo; Barisione, Emanuela; Centanni, Stefano; Castaldo, Nadia; Corcione, Silvia; De Rosa, Francesco Giuseppe; Di Marco, Fabiano; Gori, Andrea; Gramegna, Andrea; Granata, Guido; Gratarola, Angelo; Maraolo, Alberto Enrico; Mikulska, Malgorzata; Lombardi, Andrea; Pea, Federico; Petrosillo, Nicola; Radovanovic, Dejan; Santus, Pierachille; Signori, Alessio; Sozio, Emanuela; Tagliabue, Elena; Tascini, Carlo; Vancheri, Carlo; Vena, Antonio; Viale, Pierluigi; Blasi, Francesco

INTRODUCTION: The Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP) constituted an expert panel for developing evidence-based guidance for the clinical management of adult patients with coronavirus disease 2019 (COVID-19) outside intensive care units. METHODS: Ten systematic literature searches were performed to answer ten different key questions. The retrieved evidence was graded according to the Grading of Recommendations Assessment, Development, and Evaluation methodology (GRADE). RESULTS AND CONCLUSION: The literature searches mostly assessed the available evidence on the management of COVID-19 patients in terms of antiviral, anticoagulant, anti-inflammatory, immunomodulatory, and continuous positive airway pressure (CPAP)/non-invasive ventilation (NIV) treatment. Most evidence was deemed as of low certainty, and in some cases, recommendations could not be developed according to the GRADE system (best practice recommendations were provided in similar situations). The use of neutralizing monoclonal antibodies may be considered for outpatients at risk of disease progression. For inpatients, favorable recommendations were provided for anticoagulant prophylaxis and systemic steroids administration, although with low certainty of evidence. Favorable recommendations, with very low/low certainty of evidence, were also provided for, in specific situations, remdesivir, alone or in combination with baricitinib, and tocilizumab. The presence of many best practice recommendations testified to the need for further investigations by means of randomized controlled trials, whenever possible, with some possible future research directions stemming from the results of the ten systematic reviews. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40121-021-00487-7.